EFSA Health Claims Explained: What 'Normal Bowel Function' Actually Means

If you have ever looked at a fiber supplement sold in Europe, you may have noticed a small line of text on the packaging: “Chicory inulin contributes to normal bowel function by increasing stool frequency.” That sentence took over a decade of research, six human intervention studies, and a regulatory review by one of the most demanding food safety agencies in the world.

This is an EFSA-authorized health claim. And it changes how you should think about every fiber product on the shelf.

→ Read: The European Fiber Gap

What is EFSA?

The European Food Safety Authority is the EU’s independent scientific body responsible for evaluating claims that food companies want to print on their packaging. When a supplement brand in Europe says its product “supports digestive health” or “contributes to normal bowel function,” that language is not marketing copy. It is regulated text, evaluated against clinical evidence.

EFSA operates under Regulation (EC) No 1924/2006, which has governed nutrition and health claims across the European Union since July 1, 2007.¹ The regulation exists for a simple reason: to stop companies from printing whatever they want on food labels.

The bar is high. Since the regulation took effect, EFSA has rejected approximately 90% of all health claim submissions. Out of more than 2,300 applications, only around 267 have been authorized. Every authorized claim has survived scrutiny from EFSA’s Panel on Dietetic Products, Nutrition and Allergies. That panel reviews the clinical evidence, the study design, the dosage, the population studied, and whether the claimed effect is actually a beneficial physiological outcome.

If a claim makes it through this process, it means something.

What are the three types of health claims?

Not all health claims work the same way. The regulation creates distinct categories, each with different evidence requirements.

Article 13.1 claims are general function claims. These cover well-established relationships between a nutrient and a body function. Think “calcium contributes to normal bone maintenance” or “vitamin C contributes to the normal function of the immune system.” These were evaluated in bulk. EFSA received over 44,000 submissions from member states, consolidated them into roughly 4,600 entries, and published opinions on each. The surviving claims appear on a public register that any food business can use, provided their product meets the specified conditions.

Article 13.5 claims are based on newly developed scientific evidence or include a request for proprietary data protection. This is the route for companies that have invested in their own clinical research and want exclusive use of the claim. If EFSA authorizes an Article 13.5 claim, the applicant gets five years of proprietary use. After that, anyone whose product meets the conditions can use the same claim.

Article 14 claims cover disease risk reduction and children’s development. These have the highest evidence bar. An example: “Plant stanol esters have been shown to reduce blood cholesterol. Blood cholesterol is a risk factor in the development of coronary heart disease.”

For fiber supplements, the most relevant category is Article 13.5. And there is exactly one authorized bowel function claim for a specific fiber ingredient.

What is the chicory inulin health claim?

In 2014, BENEO-Orafti S.A., a subsidiary of BENEO GmbH (Mannheim, Germany) within the Südzucker Group, submitted an Article 13.5 application through the Belgian competent authority (EFSA-Q-2014-00403). BENEO-Orafti S.A. is based in Tienen, Belgium. The application was for their ingredient, native chicory inulin, and the claimed effect was maintenance of normal defecation by increasing stool frequency.²

EFSA’s NDA Panel published its scientific opinion on January 9, 2015. The conclusion: a cause-and-effect relationship had been established. Six human intervention studies involving 86 subjects consistently showed that consumption of native chicory inulin at a dose of at least 12 grams per day increases stool frequency.

The authorized claim reads: “Chicory inulin contributes to normal bowel function by increasing stool frequency.”

Commission Regulation (EU) 2015/2314 formally authorized the claim on December 7, 2015, with proprietary use for BENEO beginning January 1, 2016.³ The five-year proprietary period has since expired, meaning any food business can now use this claim, provided their product contains native chicory inulin at the specified dose.

We cover the full science behind this ingredient, including the broader 2022 meta-analysis of 50 trials and the Frutalose refusal, in our chicory inulin deep dive.

A few things make this claim unusual.

The specificity. This is not a generic “fiber supports digestion” statement. It names the ingredient (chicory inulin), the mechanism (increasing stool frequency), and the dose (12g/day). Most authorized claims are broader.

The ingredient definition. “Native chicory inulin” is precisely defined: a non-fractionated mixture of monosaccharides (less than 10%), disaccharides, inulin-type fructans, and inulin extracted from chicory root, with a mean degree of polymerization of 9 or higher. Not all inulin qualifies. Synthetic FOS, hydrolyzed inulin from other sources, or blends that do not match this chemical profile cannot carry the claim.

The dose lock. 12 grams per day. Not 5g, not 8g. The studies that EFSA evaluated used this specific amount, and the authorization is tied to it. A product containing 6g of inulin per serving cannot use this claim unless the label directs consumers to take two servings.

→ Read: Chicory Inulin vs. Psyllium Husk: Which Fiber for Wegovy Users?

What does “normal bowel function” actually mean?

The phrase sounds clinical because it is. EFSA defines “maintenance of normal defecation” as a beneficial physiological effect, provided it does not result in diarrhea. The Panel assesses this through several measurable outcomes: stool frequency, stool consistency, sensation of complete or incomplete evacuation, fecal bulk, and transit time.

For the chicory inulin claim specifically, the primary outcome was stool frequency. The six studies showed an increase of approximately one additional bowel movement per week at the 12g/day dose. That is a modest but consistent and clinically meaningful effect.

This is worth understanding because it sets realistic expectations. Chicory inulin at 12g/day will not transform your digestion overnight. It will, based on the evidence EFSA reviewed, produce a measurable increase in regularity over time.

Why does this matter when comparing supplements?

Walk into any pharmacy in Germany, Spain, or France and you will find fiber supplements making various claims. Some say “supports digestive health.” Others say “promotes regularity.” A few say nothing at all.

Here is how to read the landscape.

Products carrying the EFSA Article 13.5 claim have the strongest regulatory backing available in Europe for a fiber bowel function claim. The wording must be exact: “Chicory inulin contributes to normal bowel function by increasing stool frequency.” If a product uses this language, it means it contains native chicory inulin meeting the EFSA specification and delivers at least 12g/day at the recommended dose.

Products using Article 10.3 well-being claims can make broader but less specific statements like “chicory inulin promotes digestive health” or “chicory root fiber supports a healthy and balanced digestive system.” These are permitted as accompaniments to authorized claims but are softer, less specific, and do not require the same level of evidence.

Products making no specific claim are either using a fiber type without an authorized claim (psyllium, acacia, guar gum) or are not meeting the conditions of use for any authorized claim. This does not mean the product is ineffective. It means the evidence has not been evaluated and authorized through the EFSA process.

Products sold from the US operate under a completely different system. The FDA allows “structure/function claims” that do not require pre-approval. A US supplement can say “supports digestive health” without submitting clinical evidence to a regulatory body. The claim is the manufacturer’s responsibility, not the regulator’s. This is why US and EU supplement labels often look different even when the product inside is identical.

→ Read: The Complete Guide to Fiber and GLP-1 Medications

What about other fibers?

Psyllium husk, one of the most widely used fiber supplements globally, does not have an EFSA Article 13.5 bowel function claim. This does not mean psyllium is ineffective. There is substantial clinical evidence for psyllium’s effects on regularity, cholesterol, and glycemic response. But no company has submitted and received authorization for a psyllium-specific bowel function claim through the EFSA process.

Beta-glucan (from oats and barley) has authorized EFSA claims for cholesterol reduction and post-meal blood sugar response. These are Article 13.1 general function claims, not Article 13.5 proprietary claims.

Wheat bran fiber has an EFSA-authorized claim for acceleration of intestinal transit.

The absence of an EFSA claim is not evidence of ineffectiveness. The EFSA process requires a specific applicant, a specific dossier, and significant investment in clinical research. Many effective ingredients simply have not been submitted.

But when an ingredient has gone through the process and received authorization, that is a signal worth paying attention to.

The bottom line

EFSA health claims are not marketing. They are regulatory conclusions backed by clinical evidence and reviewed by an independent scientific panel that rejects 9 out of 10 submissions.

Chicory inulin at 12g/day has the only authorized Article 13.5 claim for maintenance of normal bowel function among fiber ingredients in Europe. That claim is specific, dose-locked, and ingredient-defined.

When you are comparing fiber supplements, especially if you are managing side effects from GLP-1 medications, understanding this distinction matters. The label tells you more than you think.